因信息披露违法违规被立案后，监管对嘉应制药（002198）及相关责任人的处罚落地。此前公司在5月 28日晚曾公告，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。（详见本报5月29日报道 本报报道后，002198被立案调查了！） 8月3日晚间，嘉应制药公告，8月1日，公司及相关责任人李能（现任董事长）、游永平（现任董事、总 经理）、史俊平（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（以下简 称《行政处罚书》），因2.2亿元关联资金拆借未及时披露，嘉应制药及相关责任人合计领490万元罚 单。 嘉应制药及相关责任人领490万元罚单 《行政处罚书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称"药聚能"）的实际控 制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需求，嘉 应制药的子公司嘉应制药（湖南）有限公司（以下简称"湖南嘉应"）以月初转出、月末转回的方式，向 药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2 ...

Core Viewpoint - The recent policy change reinstates the value-added tax (VAT) on interest income from newly issued government bonds, local government bonds, and financial bonds starting from August 8, but provides a tax exemption for individual investors under certain conditions [1] Group 1: Tax Policy Changes - The State Taxation Administration has issued a guideline indicating that individuals purchasing government bonds and similar securities will be exempt from VAT on interest income if their monthly sales do not exceed 100,000 yuan [1] - The exemption applies to a quarterly sales limit of 300,000 yuan, allowing individuals to benefit from this tax relief [1] - This tax exemption policy is set to remain in effect until December 31, 2027, with future extensions yet to be determined [1]

Core Viewpoint - The restoration of value-added tax (VAT) on interest income from newly issued government bonds, local government bonds, and financial bonds is expected to generate over 30 billion yuan in revenue this year [1][4]. Tax Policy Changes - Starting from August 8, 2025, VAT will be reinstated on interest income from newly issued government bonds, local government bonds, and financial bonds, reversing the previous exemption policy [2][3]. - Individuals purchasing these bonds will be exempt from VAT on interest income if their monthly sales do not exceed 100,000 yuan, applicable until December 31, 2027 [1][2]. Financial Impact - The reinstatement of VAT is projected to increase tax revenue by approximately 315.5 billion yuan, with commercial banks expected to bear the largest tax burden, estimated at 232.7 billion yuan [4]. - Future tax revenue is expected to grow significantly, with estimates of 321 billion yuan in 2025, 648 billion yuan in 2026, and 988 billion yuan in 2027 as the taxable bond market expands [5]. Market Reactions - Analysts suggest that the tax increase will reduce the yield for bond investors, potentially leading to a decrease in demand for government and local bonds [3]. - The impact on bond market trends is considered to be limited, as the tax change is viewed as a one-time event, with any cost increases likely to be shared between issuers and investors [3].

证券之星消息，8月1日医药商业板块较上一交易日上涨1.43%，达嘉维康领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 603883 | 老百姓 | 19.21 | -1.49% | | 18.34万 | 3.54Z | | 301015 | 百洋医药 | 21.97 | -0.45% | | 10.05万 | 2.22亿 | | 600829 | 人民同泰 | 8.30 | 0.24% | | 18.88万 | 1.57亿 | | 600056 | 中国医药 | 11.08 | 0.36% | | 30.82万 | 3.43亿 | | 000950 | 重药控股 | 5.32 | 0.57% | | 20.35万 | 1.09亿 | | 603233 | 大参林 | 17.42 | 0.64% | | 4.04万 | 7047.76万 | | 6 ...

Core Viewpoint - Neta Automobile is facing severe financial difficulties, with a reported debt of 18.3 billion and a significant decline in sales performance, leading to employee unrest and consumer dissatisfaction [4][26][30]. Group 1: Financial Situation - Neta Automobile's revenue losses have escalated to 6.867 billion, with total losses exceeding 18 billion over three years [26]. - The company has liabilities amounting to 57.6 billion against a mere 2.837 billion in assets, indicating a dire financial state [26][30]. - Recent reports indicate that Neta's production lines have been halted for eight months due to financial constraints, leading to a backlog of unpaid wages and unresolved consumer issues [28][30]. Group 2: Employee and Consumer Impact - Employees have faced salary cuts and layoffs, leading to protests for unpaid wages, with some employees unable to access company premises [6][11]. - Consumers who have paid deposits for vehicles are experiencing delays in delivery, with many reporting issues with vehicle functionality and lack of available parts for repairs [18][20][22]. - The company has received numerous complaints regarding vehicle malfunctions, with hundreds of cases related to the inability to obtain necessary replacement parts [22][23]. Group 3: Attempts at Recovery - Neta Automobile has attempted to recruit investors for bankruptcy restructuring, with 44 potential investors expressing interest in reviving the company [32]. - There are plans for some employees to return in August to address outstanding customer service issues, indicating a potential path towards recovery [34]. - The company has previously tried self-rescue measures, such as debt-to-equity swaps, but these efforts have not been successful [30].

老百姓表示，本次权益变动为股东履行此前披露的减持计划，不触及要约收购，本次减持事项与股东此前已披露的计划、承诺一 致。截至公告披露日，本次减持股份计划尚未实施完毕。本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公司 治理结构及持续经营产生重大影响。 | 投资者名 称 | 变动前股 数(万股) | 变动前比 例 (%) | 变动后股 数(万股) | 变动后比 例 (%) | 权益变动 方式 | 权益变动 的 | 资金来源 (仅增持 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 时间区间 | 填写) | | 发生直接持股变动的主体: | | | | | | | | | 老百姓医 药集团有 | 19, 856. 41 | 26. 12 | 18, 045. 34 | 23. 74 | 集中竞价 | 2025/6/20 | | | 限公司 | 75 | | 75 | | 大宗交易 | 2025/7/30 | | | | | | | | V | | | | 未发生直接持股变动的主体: | | | | | | | | | ...

公司控股股东老百姓医药集团有限公司及其一致行动人陈秀兰女士保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。本公司董事会及全体董事保证公告内容与信息披露 义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：本公告表格中如存在总计数与各分项数值之和尾数不符的情况，均为四舍五入原因形成 三、其他说明 １、本次权益变动为股东履行此前披露的减持计划，不触及要约收购，本次减持事项与股东此前已披露 的计划、承诺一致。截至本公告披露日，本次减持股份计划尚未实施完毕。 2、本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公司治理结构及持续经营产生 重大影响。 ■ 3.一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 公司于2025年7月31日收到公司控股股东老百姓医药集团有限公司的通知，其于2025年6月20日、6月23 日、7月30日通过集中竞价交易和大宗交易方式合计减持公司股份18,110,700股，占公司总股本的 2.38%。控股股东老百姓 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-035 老百姓大药房连锁股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度 的提示性公告 公司控股股东老百姓医药集团有限公司及其一致行动人陈秀兰女士保 证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。本公司董事会及全体董事保证公告内容与信息披露义务人提供 的信息一致。 重要内容提示： 权益变动方向 比例增加□ 比例减少√ 权益变动前合计比例 27.91% 权益变动后合计比例 25.53% 本次变动是否违反已作出的承 是□ 否√ 诺、意向、计划 是否触发强制要约收购义务 是□ 否√ 一、 信息披露义务人及其一致行动人的基本信息 √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 投资者及其一致行动人的身份 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他 信息披露义务人名称 投资者身份 统一社会信用代码 √ 控股股东/实控人 老百姓医药集团有限 □ 控股股东/实控人的一致 公司 行动人 □ 其他直接持股股东 一致行动人名称 投资者身份 统一社会信用代码 √ 控股 ...

Core Viewpoint - The establishment of national parks in China has achieved significant results over the past decade, with a focus on ecological protection and public benefits [1][2]. Group 1: Achievements in National Park Construction - China has officially established several national parks, including Sanjiangyuan, Giant Panda, Northeast Tiger and Leopard, Hainan Tropical Rainforest, and Wuyi Mountain, marking a decade of national park system reform [1]. - The population of wild giant pandas has increased from approximately 1,100 in the 1980s to around 1,900 today, indicating successful conservation efforts [1]. - Ecosystems in regions such as the Yangtze, Yellow, and Lancang Rivers have been effectively protected, showcasing the positive impact of national park initiatives [1]. Group 2: Public Benefits and Accessibility - National parks provide direct and indirect benefits to the public, allowing citizens to experience and appreciate China's natural beauty [1][2]. - The construction of national parks is linked to essential human needs, such as clean air and water, positioning them as vital ecological systems that contribute to climate stability and environmental health [2]. - The concept of "universal public welfare" is emphasized, with proposals for low ticket prices and free access for specific groups, ensuring equitable access to national parks [2].

格隆汇7月31日丨老百姓(603883.SH)公布，公司于2025年7月31日收到公司控股股东老百姓医药集团有 限公司的通知，其于2025年6月20日、6月23日、7月30日通过集中竞价交易和大宗交易方式合计减持公 司股份1811.07万股，占公司总股本的2.38%。控股股东老百姓医药集团有限公司及其一致行动人陈秀兰 合计持股比例由27.91%减少至25.53%，本次权益变动触及1%刻度。 ...